Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes
Short-term eculizumab therapy is promising for rescuing ABOi KT recipients with high anti-ABO antibody titers refractory to plasmapheresis-based desensitization therapy.
Authors
- Juhan Lee (ORCID: https://orcid.org/0000-0003-4910-2596)
- Beom Seok Kim (ORCID: https://orcid.org/0000-0002-5732-2583)
- Kyu Ha Huh (ORCID: https://orcid.org/0000-0003-1364-6989)
- Minsun Jung (ORCID: https://orcid.org/0000-0002-8701-4282)
- Ga Young Heo (ORCID: https://orcid.org/0000-0003-0913-5289)
- Honglin Piao (ORCID: https://orcid.org/0000-0003-4829-6157)
- Jaeseok Yang (ORCID: https://orcid.org/0000-0002-5378-7797)
- Hyung Woo Kim (ORCID: https://orcid.org/0000-0002-6305-452X)
- Hyun‐Jeong Kim (ORCID: https://orcid.org/0000-0003-4608-2120)
Institutions
- Yonsei University (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3389/fimmu.2024.1465851
- Citations
- 4
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.03
Funders
- Yonsei University
- Yonsei University College of Medicine